Glaukos (NYSE:GKOS) Shares Down 7.4% – Here’s What Happened

Glaukos Corporation (NYSE:GKOS)’s share price fell 7.4% on Friday . The stock traded as low as $135.49 and last traded at $128.7890. 176,904 shares were traded during mid-day trading, a decline of 77% from the average session volume of 781,936 shares. The stock had previously closed at $139.03.

Key Stories Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Zacks Research raised its Q1 2027 EPS estimate and modestly improved its FY2026 loss forecast, indicating slightly better-than-expected medium-term earnings potential.
• Neutral Sentiment: The analyst maintained a generally bullish long-term view, with FY2028 EPS still projected to turn positive and grow meaningfully over time.
• Negative Sentiment: Zacks Research cut estimates for Q2 2026, Q3 2026, and Q4 2026, signaling weaker near-term profitability expectations.
• Negative Sentiment: The firm also lowered FY2027 and FY2028 EPS estimates, which may have pressured investor sentiment around Glaukos’ longer-term earnings trajectory.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on GKOS. Wells Fargo & Company lifted their price target on Glaukos from $135.00 to $138.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Stifel Nicolaus set a $170.00 price target on Glaukos in a research note on Thursday, April 30th. William Blair upgraded Glaukos to a “strong-buy” rating in a research note on Friday, January 30th. Wall Street Zen upgraded Glaukos from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, Needham & Company LLC lifted their price target on Glaukos from $127.00 to $136.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $146.17.

Glaukos Trading Down 7.7%

The company has a 50 day simple moving average of $119.83 and a 200 day simple moving average of $113.29. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.73 and a current ratio of 5.43. The company has a market capitalization of $7.53 billion, a PE ratio of -39.17 and a beta of 0.94.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.12. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The company had revenue of $150.57 million during the quarter, compared to analyst estimates of $137.00 million. During the same period in the previous year, the business earned ($0.22) EPS. Glaukos’s quarterly revenue was up 41.2% on a year-over-year basis. Analysts anticipate that Glaukos Corporation will post -0.57 earnings per share for the current year.

Insider Transactions at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $140.76, for a total transaction of $703,800.00. Following the completion of the sale, the director directly owned 35,528 shares in the company, valued at approximately $5,000,921.28. The trade was a 12.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Joseph E. Gilliam sold 19,573 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $143.54, for a total value of $2,809,508.42. Following the sale, the chief operating officer owned 73,419 shares of the company’s stock, valued at approximately $10,538,563.26. This trade represents a 21.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 45,930 shares of company stock valued at $6,321,363 in the last 90 days. Corporate insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Glaukos

Several large investors have recently bought and sold shares of GKOS. AQR Capital Management LLC increased its stake in Glaukos by 2.6% during the 1st quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock worth $766,000 after buying an additional 198 shares in the last quarter. Jones Financial Companies Lllp boosted its holdings in shares of Glaukos by 1,405.9% during the 1st quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock worth $252,000 after purchasing an additional 2,390 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Glaukos by 41.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock worth $22,636,000 after purchasing an additional 67,668 shares during the last quarter. M&T Bank Corp acquired a new position in shares of Glaukos during the 2nd quarter worth approximately $203,000. Finally, Gamco Investors INC. ET AL boosted its holdings in shares of Glaukos by 10.7% during the 2nd quarter. Gamco Investors INC. ET AL now owns 8,001 shares of the medical instruments supplier’s stock worth $826,000 after purchasing an additional 773 shares during the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.